PMID- 9649695
OWN - NLM
STAT- MEDLINE
DCOM- 19990119
LR  - 20131121
IS  - 1167-1122 (Print)
IS  - 1167-1122 (Linking)
VI  - 8
IP  - 4
DP  - 1998 Jun
TI  - Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin 
      monochemotherapy in the treatment of metastatic melanoma.
PG  - 235-9
AB  - The anti-tumoral activity of interleukin-2 (IL-2) is well-documented. Although 
      the response rate with this cytokine is low, it appears to be improved when 
      associated with interferon-alpha (INF-alpha) and/or cytotoxic drugs. Aim of this 
      work was to study the efficacy and tolerance of an ambulatory treatment using 
      subcutaneous, low-dose IL-2 with subcutaneous INF-alpha and chemotherapy. We 
      report a multicenter study of ambulatory treatment combining subcutaneous (SC) 
      low-dose IL-2 (9 x 10(6) IU) with SC INF-alpha-2a (3 x 10(6) IU) and cisplatin 
      (100 mg/m2) in 33 patients (13 women and 20 men, 22 to 66 years of age) with 
      metastatic malignant melanoma. Metastases were mainly nodal (54.5%) and pulmonary 
      (51.5%). For 81.8% of patients, this therapy constituted the firstline treatment. 
      The overall response rate at the end of the first maintenance course was 30.3% (3 
      complete responses and 7 partial responses). Adverse effects were observed in 28 
      patients (84.8%), but were most often minor (grade 1 or 2 on the WHO toxicity 
      scale). The results confirmed the good tolerance to SC IL-2 and its suitability 
      for ambulatory therapy, as well as the potential benefit of associating IL-2 with 
      cisplatin in the treatment of metastatic melanoma (a possibility considered in 
      two previous studies).
FAU - Andres, P
AU  - Andres P
AD  - Department of Dermatology, Hotel-Dieu, CHU place A.-Ricordeau, 44093 Nantes Cedex 
      01, France.
FAU - Cupissol, D
AU  - Cupissol D
FAU - Guillot, B
AU  - Guillot B
FAU - Avril, M F
AU  - Avril MF
FAU - Dreno, B
AU  - Dreno B
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - France
TA  - Eur J Dermatol
JT  - European journal of dermatology : EJD
JID - 9206420
RN  - 0 (Interferon-alpha)
RN  - 0 (Interleukin-2)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Ambulatory Care
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Cisplatin/administration & dosage
MH  - Female
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Interferon-alpha/*administration & dosage
MH  - Interleukin-2/*administration & dosage
MH  - Liver Neoplasms/secondary
MH  - Lung Neoplasms/secondary
MH  - Lymphatic Metastasis
MH  - Male
MH  - Melanoma/*drug therapy/mortality/pathology/secondary
MH  - Middle Aged
MH  - Prognosis
MH  - Skin Neoplasms/*drug therapy/mortality/pathology
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 1998/07/03 00:00
MHDA- 1998/07/03 00:01
CRDT- 1998/07/03 00:00
PHST- 1998/07/03 00:00 [pubmed]
PHST- 1998/07/03 00:01 [medline]
PHST- 1998/07/03 00:00 [entrez]
PST - ppublish
SO  - Eur J Dermatol. 1998 Jun;8(4):235-9.